Should Investors Buy Eli Lilly Stock?
Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies.
Predicted Price is the pryogiTM prediction of where the price is going in next 3-4 quarters. There may be a revision of the predicted price every 3 months from the date of publication of the first predicted price of the stock. Price on Report Date is the price of the stock on the day prediction was published by pryogiTM. Current price shows the current price of the stock.
Margin of error shows range the price will end up in dollars either above or below the predicted price. Margin of error percentage shows the price will end up in percentage either above or below the predicted price.
Expected Returns from report date shows the returns (positive or negative) from published prediction date if you bought the stock on report date. Expected Returns from today shows the returns from today if you buy the stock today. A positive expected returns indicates a profit you will make, a negative expected return indicates a loss you will make if you buy the stock. There are different strategies to apply in the stock market for profit and loss, pryogiTM will publish such strategies in the future to help you.
PryogiTM meter shows you predicted price, price on the date this prediction was published(report date) and price of the stock today on a price scale. This indicates if the stock price is moving towards or away from the predicted price
PryogiTM performance chart shows actual movement of stock price from prediction published date(report date) and if the price is moving towards or away from predicted price
Investors are excited about the company's weight loss treatments but might be overlooking the exciting pipeline of new therapies.
Investors with a lot of money to spend have taken a bearish stance on Eli Lilly ( NYSE:LLY ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Bill Gates and the Pan American Health Organization ( PAHO ) are reportedly developing plans to expand access to popular weight-loss drugs such as Novo Nordisk A/S' ( NYSE:NVO ) Wegovy and Eli Lilly and Co.'s ( NYSE:LLY ) Mounjaro in low- and middle-income countries.
NVO's $4.7B acquisition of Akero Therapeutics adds a late-stage MASH therapy to its obesity-linked pipeline, advancing its expansion goal beyond semaglutide.
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Ongoing developments make these companies look attractive.
Eli Lilly (LLY) reached $855.35 at the closing of the latest trading day, reflecting a +1.14% change compared to its last close.
Underneath the glitz of artificial intelligence, cloud computing and advanced mobility is an elite group of publicly traded innovators known as the Magnificent Seven. Earlier this summer, these powerhouse enterprises combined represented a record-breaking $19.4 trillion in market capitalization.
NVO's 10% stock price rally masks deeper challenges as competition, restructuring and slower growth weigh on its outlook.
Lilly's explosive GLP-1 growth and AbbVie's post-Humira rebound set up a fierce 2025 showdown between two pharma powerhouses.
Roche has a promising GLP-1 drug that is entering phase 3 trials.
An official report on October 7, 2025 reveals Representative David Taylor's recent purchase of Procter & Gamble ( NYSE:PG ) stock, valued between $5,005 and $75,000. The transaction took place on September 22, 2025, as per the October filing.
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Securities raised Flex Ltd. ( NYSE:FLEX ) price target from $58 to $65.
Investors should buy stakes in AI-powered stocks with scalable, asset-light business models.
A Strong Alternative Energy Stock and a Solid Drug Stock are in Focus.
Investors with a lot of money to spend have taken a bullish stance on Eli Lilly ( NYSE:LLY ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
Eli Lilly and Co. ( NYSE:LLY ) unveiled new data on Tuesday from LUCENT-3, the single-arm long-term Phase 3 open-label extension of LUCENT-1 and LUCENT-2, which evaluated the efficacy and safety of mirikizumab in patients with ulcerative colitis for an additional three years of treatment ( up to ...
After nearly two years of sideways price action, Eli Lilly stock could soar to new highs between now and 2030.
Zacks.com users have recently been watching Lilly (LLY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Eli Lilly ( NYSE:LLY ) has outperformed the market over the past 10 years by 13.78% on an annualized basis producing an average annual return of 26.64%. Currently, Eli Lilly has a market capitalization of $757.36 billion.
Eli Lilly and Co. ( NASDAQ:LLY ) plans to invest over $1 billion in India to strengthen its manufacturing network, according to Reuters. The move aims to tap into the country's skilled workforce and support Lilly's global expansion.
LLY shares have jumped 16% last week as Pfizer's landmark government deal boosted investor confidence across the pharma sector.
ABBV shares rose 6% last week as optimism swept the pharma sector after Pfizer's landmark drug-pricing deal with the Trump administration.
Zacks Value Trader weighs whether big pharma names like Pfizer, Merck, AbbVie, Eli Lilly and Novo Nordisk are genuine bargains or value traps.
Eli Lilly (LLY) closed the most recent trading day at $839.87, moving +2.44% from the previous trading session.
Wall Street soared to fresh record highs at the end of the week, brushing aside the 21st U.S. government shutdown in history and a missing jobs report, as investors doubled down on bets for interest rate cuts and cheered strong gains in pharmaceutical and AI-driven tech stocks.
Pfizer's deal with the Trump administration raised hopes that Eli Lilly would also avoid pharmaceutical tariffs.
Merck shares climb nearly 14% as Pfizer's landmark drug pricing deal with the Trump administration sparked renewed optimism in pharma stocks.
Financial giants have made a conspicuous bullish move on Eli Lilly. Our analysis of options history for Eli Lilly ( NYSE:LLY ) revealed 18 unusual trades. Delving into the details, we found 50% of traders were bullish, while 22% showed bearish tendencies.
Pfizer surges 14% after landmark Trump deal slashing drug prices while boosting U.S. investments.
By investing in quality growth stocks, you can put yourself in an excellent position to earn a great return.
Eli Lilly And Company ( NYSE:LLY ) shares are trading higher Wednesday after President Donald Trump recently announced a deal with Pfizer as well as the 'TrumpRx' site to decrease prices. What To Know: Pfizer agreed to provide medicines on the TrumpRx platform at steep discounts and extend ...
Pfizer Inc's ( NYSE:PFE ) deal with Washington isn't just a handshake in the Oval Office - it's a seismic jolt to America's drug-pricing game.
Wall Street closed higher on Tuesday, driven by healthcare stocks.
Pfizer surged after striking a landmark agreement with the Trump administration to lower drug prices and expand U.S. production.
Novo Nordisk is expanding beyond Wegovy and Ozempic with next-generation obesity candidates and strategic deals to defend its market lead.
The average brokerage recommendation (ABR) for Lilly (LLY) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
It's hard to keep these longtime winners down for too long.
Market leaders riding secular tailwinds are likely to be profitable long-term investments.
Investors with a lot of money to spend have taken a bullish stance on Eli Lilly ( NYSE: LLY ) . We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga. Whether these are institutions or just wealthy individuals, we don't know.
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
The pharmaceutical company had a clinical setback earlier this year, but that's now in the rearview mirror.
Could investing in this stock be an underrated way to profit from the rapidly expanding AI industry?
Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc ( NASDAQ: AMGN ) announced a $650 million expansion of its U.S. manufacturing network.
AstraZeneca Plc ( NASDAQ: AZN ) launched AstraZeneca Direct, an online platform designed to create a simple, convenient way for eligible patients to access their prescribed medications at a transparent cash price with home delivery.
ABBV eyes a 2025 rebound as Skyrizi and Rinvoq drive growth beyond Humira, with oncology and neuroscience adding momentum.